Population study: atopic dermatitis affects 7.3% of Americans

  • J Invest Dermatol

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A population-based study estimates an atopic dermatitis (AD) prevalence of 7.3%, and patients tend to have worse QoL and increased risk of anxiety or depression.

Why this matters

  • Based on these prevalence estimates, 16.5 million adults would have a diagnosis of AD, with 6.6 million meeting criteria for moderate-to-severe disease. 

Key results

  • Overall AD prevalence was 7.3%.
  • 60.1% of cases were classified as mild, 28.9% as moderate, and 11.0% as severe.
  • Marital status and level of education were associated with severity in adjusted analysis.
  • Patients with AD had higher mean scores in the dermatology life quality index (4.71 vs 0.97; OR, 8.33; P<.001 in adjusted model>
  • Patients with AD had higher odds of clinical anxiety and depression (Hospital Anxiety and Depression scale; OR, 3.29 [P<.001 and respectively in adjusted analysis>

Study design

  • 1278 adults completed a Gfk web survey concerning AD prevalence, severity, and effects on QoL.
  • Funding: Asthma and Allergy Foundation of America in partnership with the National Eczema Association sponsored by Sanofi Genzyme and Regeneron.

Limitations

  • Potential misclassification or recall bias.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit